The effects of taxifolin on neuropathy related with hyperglycemia and neuropathic pain in rats: A biochemical and histopathological evaluation

Background. Hyperglycemia can be considered a determining factor in the development of diabetic neuropathy as well as neuropathic pain. There is a relationship between the excessive production of reactive oxygen species (ROS) and the pathogenesis of diabetic neuropathic pain. Taxifolin, on the other hand, is a flavonoid that has been documented to inhibit ROS production. Objectives. To investigate the effects of taxifolin, which has antioxidant and neuroprotective effects, on alloxan-induced hyperglycemia-induced neuropathy and neuropathic pain, biochemically and histopathologically. Materials and methods. The albino Wistar male rats were divided into 3 groups: Healthy group (HG), only alloxan group (AXG) and alloxan+taxifolin group (ATG). Hyperglycemia in animals was caused through intraperitoneal injection of alloxan at a dose of 120 mg/kg. Paw pain thresholds of animals were measured using Basile algesimeter. Sciatic nerve tissues were examined biochemically and histopathologically in order to evaluate neuropathy. Results. Our experimental results revealed that taxifolin significantly prevented the increase of plasma glucose concentration level with alloxan administration, the decrease of the paw pain threshold related to hyperglycemia, the change of oxidant-antioxidant balance in the sciatic nerve tissue in favor of oxidants, and the deterioration of tissue morphology in animals. Conclusions. Our experimental results indicate that taxifolin alleviates alloxan-induced hyperglycemia-related neuropathy and neuropathic pain

Febrile neutropenia due to brucellosis: Case report Bruselloza baǧlı bir febril nötropeni olgusu

Brucellosis is a common zoonotic disease which is common in our country. It has a quite broad spectrum that includes a certain number of hematologic disorders such as neutropenia, thrombocytopenia and anemia. A thirty-seven-year-old female patient presented with fever with chill as well as fatigue. Physical examination and laboratory analyses revealed splenomegali, fever and pancytopenia. The diagnosis was established based on blood culture and brucella tube agglutination test (1/320). The patient was treated with rifampycin 600 g/day and doxycycline 200 mg/day for six weeks. Her fever subsided on the 5th day of treatment and pancytopenia recovered on the 15th day

The association of Visfatin levels with metabolic parameters and inflammation in diabetic nephropathy

© 2020, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.To investigate the visfatin levels at the stages of diabetic nephropathy(DNP), changes in visfatin levels according to stages of DNP, and the association of visfatin levels with other anti-inflammatory parameters including high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumor necrosis factor alpha(TNFα). Patients were divided into 4 groups based on the glomerular filtration rate (GFR) and albuminuria as follows; Group I: Albuminuria60ml/min, Group II:albuminuria 30 to 300 mg per day and GFR>60ml/min, Group III:albuminuria>300mg per day and GFR>60ml/min, and Group IV: Albuminuria>300 mg per day and GFR<60 ml/min. Of the 141 patients included in the study, 83(58.8%) were female. The mean age of patients was 55.3±8.2 years. Microalbuminuria was found to be 10.1±9.8 mg per day in group I, 89.4±68.2 mg per day in group II, 525.1±280.7 mg per day in group III, and 1034±1893 mg per day in group IV (p<0.001). When the correlation analysis was repeated separately in each group, there was a positive correlation between Visfatin and IL-6 levels in only group III (r=0.926; p<0.001). When the patients in group III and IV were combined in a single group and considered as macro-albuminuric, multivariate analysis showed that visfatin had a positive correlation with IL-6 (r=0.380, p=0.006) In this study, we could not determine any association between visfatin levels and other anti-inflammatory markers (IL-6, TNFα, and hsCRP). However, we found a close relationship between visfatin levels and IL-6 which is one of the most important markers of inflammation in diabetic patients with overt nephropathy, namely macro-albuminuric patients

Factors affecting survival in operated gastric cancer

In this study, our aim was to determine the possible effects of Helicobacter pylori (HP), chronic atrophic gastritis (CAG), and gastrointestinal metaplasia (GIM) on survival in operated bowel type gastric cancer patients (INT-GC). Among 548 patients, 347(63.3%) were male. The median age was 57 years. Disease-free survival (DFS) and overall survival (OS) were significantly shorter in patients with GIM than those in patients without GIM (log rank, P = 0.003 and log rank P = 0.003, respectively). Multivariate analysis showed that presence of GIM (HR, 2.1) was found to be an independent factor of worse DFS. In our study, stage pIII patients with GIM had significantly shorter DFS and OS than those without GIM (log rank p = 0.008 and log rank p = 0.001, respectively). However, in subgroup analysis of patients with GIM, there was no significant DFS and OS difference between patients with stage pI and pII disease (log rank p = 0.999, log rank p = 0.184 vs. log rank p = 0.409, log rank p = 0.281, respectively)

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANYWOS: 000459277303171…European Society for Medical Oncology, Japanese Society of Medical Oncolog

Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey

WOS: 000454014501235Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We performed targeted NGS with a gene panel covering 416 cancer-related genes to profile genetic characteristics of 69 lung adenocarcinoma patients with activating EGFR mutations and assessed the contribution of targeted NGS to exploration of genetic heterogeneity of such cohort. Result: We detected total 200 actionable genetic alterations (mean 2.9 variations per patient, range: 1-7 variations) in tumor DNA and 140 actionable genetic alterations (mean 2.0 variations per patient, range: 0-5 variations) in matched plasma ctDNA, respectively. The concurrent genes with the highest mutation rate were TP53 (observed in 72.5% patients), other uncommon EGFR mutations (observed in 21.7% patients), EGFR amplification (observed in 20.3% patients), RB1 (observed in 10.1% patients), PIK3CA (observed in 7.2% patients), and MYC (observed in 5.8% patients). NGS provides EGFR mutation detection in plasma with a test sensitivity of 88.2% and specificity of 100.0%

Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

...European Society for Medical Oncology; Japanese Society of Medical Oncolog

Do histologically aggressive subtypes of papillary thyroid microcarcinoma have worse clinical outcome than non-aggressive rapillary thyroid microcarcinoma subtypes? A multicenter cohort study

Histologically aggressive micropapillary thyroid carcinomas (PTMC) subtypes are thought to be associated with an aggressive clinical course. However, evidence for unfavorable clinical outcomes in patients with aggressive PTMC subtypes is not clear. In this study, we intended to determine the difference in clinical outcomes between patients with aggressive and non-aggressive PTMC subtypes. In this multicenter cohort study, the computer-recorded clinical and histopathological data of patients who underwent thyroid surgery between January 2000 - January 2021 in 9 referral centers and were diagnosed as PTMC were analyzed. A total of 1585 patients [female 1340 (84.5%), male 245 (15.5%), mean age 47.9 +/- 11.63 years), with a mean follow-up time of 66.55 +/- 37.16 months], were included in the study. Ninety-eight cases were diagnosed as aggressive and 1487 as non-aggressive subtypes. Persistent/recurrent disease was observed in 33 (33.7% )and 41 (2.8%) patients with aggressive and non-aggressive subtypes (p 1 cm in size. Therefore, the histopathological subtype of PTMC should be taken into consideration to tailor a personalized management plan